Inefficient Exogenous Loading of a Tapasin-dependent Peptide Onto HLA-B*44:02 Can Be Improved by Acid Treatment or Fixation of Target Cells

Overview

Journal Eur J Immunol

Specialty Allergy & Immunology

Date 2012 Jun 9

PMID 22678898

Citations 5

Authors

Vincent Stroobant

Nathalie Demotte

Rosalie M Luiten

Ralf M Leonhardt

Peter Cresswell

Aude Bonehill

Alexandre Michaux

Wenbin Ma

Arend Mulder

Benoit J Van den Eynde

Pierre van der Bruggen

Nathalie Vigneron

Affiliations

Soon will be listed here.

Abstract

Antitumor cytolytic T lymphocytes (CTLs) recognize peptides derived from cellular proteins and presented on MHC class I. One category of peptides recognized by these CTLs is derived from proteins encoded by "cancer-germline" genes, which are specifically expressed in tumors, and therefore represent optimal targets for cancer immunotherapy. Here, we identify an antigenic peptide, which is derived from the MAGE-A1-encoded protein (160-169) and presented to CTLs by HLA-B*44:02. Although this peptide is encoded by MAGE-A1, processed endogenously and presented by tumor cells, the corresponding synthetic peptide is hardly able to sensitize target cells to CTL recognition when pulsed exogenously. Endogenous processing and presentation of this peptide is strictly dependent on the presence of tapasin, which is believed to help peptide loading by stabilizing a peptide-receptive form of HLA-B*44:02. Exogenous loading of the peptide can be dramatically improved by paraformaldehyde fixation of surface molecules or by peptide loading at acidic pH. Either strategy allows efficient exogenous loading of the peptide, presumably by generating or stabilizing a peptide-receptive, empty conformation of the HLA. Altogether, our results indicate a potential drawback of short peptide-based vaccination strategies and offer possible solutions regarding the use of problematic epitopes such as the one described here.

Citing Articles

Therapeutic Cancer Vaccines-Antigen Discovery and Adjuvant Delivery Platforms.

Alarcon N, Jaramillo M, Mansour H, Sun B Pharmaceutics. 2022; 14(7).

PMID: 35890342 PMC: 9325128. DOI: 10.3390/pharmaceutics14071448.

Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Vigneron N, Ferrari V, Van den Eynde B, Cresswell P, Leonhardt R J Immunol. 2018; 201(7):1875-1888.

PMID: 30135181 PMC: 6457910. DOI: 10.4049/jimmunol.1701479.

Neoepitopes of Cancers: Looking Back, Looking Ahead.

Srivastava P Cancer Immunol Res. 2015; 3(9):969-77.

PMID: 26342008 PMC: 6722432. DOI: 10.1158/2326-6066.CIR-15-0134.

Three tapasin docking sites in TAP cooperate to facilitate transporter stabilization and heterodimerization.

Leonhardt R, Abrahimi P, Mitchell S, Cresswell P J Immunol. 2014; 192(5):2480-94.

PMID: 24501197 PMC: 3943870. DOI: 10.4049/jimmunol.1302637.

Database of T cell-defined human tumor antigens: the 2013 update.

Vigneron N, Stroobant V, Van den Eynde B, van der Bruggen P Cancer Immun. 2013; 13:15.

PMID: 23882160 PMC: 3718731.

References

Vigneron N, Peaper D, Leonhardt R, Cresswell P . Functional significance of tapasin membrane association and disulfide linkage to ERp57 in MHC class I presentation. Eur J Immunol. 2009; 39(9):2371-6. PMC: 3517023. DOI: 10.1002/eji.200939536. View

Ojcius D, Gapin L, Kourilsky P . Dissociation of the peptide/MHC class I complex: pH dependence and effect of endogenous peptides on the activation energy. Biochem Biophys Res Commun. 1993; 197(3):1216-22. DOI: 10.1006/bbrc.1993.2606. View

Tussey L, Frelinger J . Detergent enhances binding of a secreted HLA-A2 molecule to solid phase peptides. Hum Immunol. 1991; 32(3):183-93. DOI: 10.1016/0198-8859(91)90055-e. View

Vigneron N, Stroobant V, Van den Eynde B, van der Bruggen P . Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 2013; 13:15. PMC: 3718731. View

Hsu D, Paz P, Villaflor G, Rivas A, Mehta-Damani A, Angevin E . Exosomes as a tumor vaccine: enhancing potency through direct loading of antigenic peptides. J Immunother. 2003; 26(5):440-50. DOI: 10.1097/00002371-200309000-00007. View

Rock K, Gramm C, Rothstein L, Clark K, Stein R, Dick L . Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell. 1994; 78(5):761-71. DOI: 10.1016/s0092-8674(94)90462-6. View

Seed B, Aruffo A . Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A. 1987; 84(10):3365-9. PMC: 304871. DOI: 10.1073/pnas.84.10.3365. View

Pu Z, Carrero J, Unanue E . Distinct recognition by two subsets of T cells of an MHC class II-peptide complex. Proc Natl Acad Sci U S A. 2002; 99(13):8844-9. PMC: 124386. DOI: 10.1073/pnas.092260499. View

Rock K, GOLDBERG A . Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu Rev Immunol. 1999; 17:739-79. DOI: 10.1146/annurev.immunol.17.1.739. View

10.

Praveen P, Yaneva R, Kalbacher H, Springer S . Tapasin edits peptides on MHC class I molecules by accelerating peptide exchange. Eur J Immunol. 2009; 40(1):214-24. DOI: 10.1002/eji.200939342. View

11.

DIBRINO M, Parker K, Margulies D, Shiloach J, Turner R, Biddison W . Identification of the peptide binding motif for HLA-B44, one of the most common HLA-B alleles in the Caucasian population. Biochemistry. 1995; 34(32):10130-8. DOI: 10.1021/bi00032a005. View

12.

Zernich D, Purcell A, Macdonald W, Kjer-Nielsen L, Ely L, Laham N . Natural HLA class I polymorphism controls the pathway of antigen presentation and susceptibility to viral evasion. J Exp Med. 2004; 200(1):13-24. PMC: 2213310. DOI: 10.1084/jem.20031680. View

13.

Luiten R, Demotte N, TINE J, van der Bruggen P . A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. Tissue Antigens. 2000; 56(1):77-81. DOI: 10.1034/j.1399-0039.2000.560110.x. View

14.

Williams A, Peh C, Purcell A, McCluskey J, Elliott T . Optimization of the MHC class I peptide cargo is dependent on tapasin. Immunity. 2002; 16(4):509-20. DOI: 10.1016/s1074-7613(02)00304-7. View

15.

Mulder A, Kardol M, Scott Arn J, Eijsink C, Franke M, Schreuder G . Human monoclonal HLA antibodies reveal interspecies crossreactive swine MHC class I epitopes relevant for xenotransplantation. Mol Immunol. 2009; 47(4):809-15. DOI: 10.1016/j.molimm.2009.10.004. View

16.

Leonhardt R, Keusekotten K, Bekpen C, Knittler M . Critical role for the tapasin-docking site of TAP2 in the functional integrity of the MHC class I-peptide-loading complex. J Immunol. 2005; 175(8):5104-14. DOI: 10.4049/jimmunol.175.8.5104. View

17.

Vigneron N, Van den Eynde B . Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cell Mol Life Sci. 2011; 68(9):1503-20. PMC: 11114561. DOI: 10.1007/s00018-011-0658-x. View

18.

Herin M, Lemoine C, Weynants P, Vessiere F, Van Pel A, Knuth A . Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer. 1987; 39(3):390-6. DOI: 10.1002/ijc.2910390320. View

19.

Mantegazza A, Savina A, Vermeulen M, Perez L, Geffner J, Hermine O . NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood. 2008; 112(12):4712-22. PMC: 2597138. DOI: 10.1182/blood-2008-01-134791. View

20.

Akatsuka Y, Nishida T, Kondo E, Miyazaki M, Taji H, Iida H . Identification of a polymorphic gene, BCL2A1, encoding two novel hematopoietic lineage-specific minor histocompatibility antigens. J Exp Med. 2003; 197(11):1489-500. PMC: 2193899. DOI: 10.1084/jem.20021925. View